<DOC>
	<DOC>NCT00727298</DOC>
	<brief_summary>This study will be performed to evaluate and document the safety and efficacy of infliximab (RemicadeÂ®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists, gastroenterologists, and dermatologists.</brief_summary>
	<brief_title>Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)</brief_title>
	<detailed_description>The study population was chosen from a non-probability sample. The safety population consisted of all participants with at least one documented infusion of infliximab. The evaluable population consisted of all participants that were &gt;=18 years of age with a recorded indication for infliximab use, that had available baseline data, and with at least 3 infusions of infliximab within the first 16 weeks of the study. Baseline characteristics are provided for this population.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participants treated with infliximab by rheumatologists, gastroenterologists, and dermatologists for chronic inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, or Crohn's disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>